9
SAMHSA’s mission is to lead public health and service delivery eorts that promote mental health, prevent substance
misuse, and provide treatments and supports to foster recovery while ensuring equitable access and better outcomes.
1-877-SAMHSA-7 (1-877-726-4727) • 1-800-487-4889 (TDD) • www.samhsa.gov
ADVISORY
19
Johnson, R. (2019). Dening hemp: A fact sheet. Congressional Research Service. https://crsreports.
congress.gov/product/pdf/R/R44742
20
Johnson, E., Kilgore, M., & Babalonis, S. (2022). Label accuracy of unregulated cannabidiol (CBD)
products: Measured concentration vs. label claim. Journal of Cannabis Research, 4(1), 28. https://doi.
org/10.1186/s42238-022-00140-1
21
Hahn, S. M. (2020). FDA advances work related to cannabidiol products with focus on protecting public
health, providing marketing clarity. Food and Drug Administration (FDA). https://www.fda.gov/news-
events/press-announcements/fda-advances-work-related-cannabidiol-products-focus-protecting-public-
health-providing-market
22
Leas, E. C., Moy, N., McMenamin, S. B., Shi, Y., Benmarhnia, T., Stone, M. D., Trinidad, D. R., & White,
M. (2021). Availability and promotion of cannabidiol (CBD) products in online vape shops. International
Journal of Environmental Research and Public Health, 18(13), 6719. https://doi.org/10.3390/
ijerph18136719
23
Corroon, J., & Kight, R. (2018). Regulatory status of cannabidiol in the United States: A perspective.
Cannabis and Cannabinoid Research, 3(1), 190-194. https://doi.org/10.1089/can.2018.0030
24
Food and Drug Administration (FDA). (2021). FDA warns companies illegally selling over-the-counter
CBD products for pain relief. https://www.fda.gov/news-events/press-announcements/fda-warns-
companies-illegally-selling-over-counter-cbd-products-pain-relief
25
Evans, D. G. (2020). Medical fraud, mislabeling, contamination: All common in CBD products. Missouri
Medicine, 117(5), 394-399. http://www.ncbi.nlm.nih.gov/pmc/articles/pmc7723146/
26
National Conference of State Legislatures. (2021). State medical cannabis laws. https://www.ncsl.org/
research/health/state-medical-marijuana-laws.aspx
27
Brown, J. D., & Winterstein, A. G. (2019). Potential adverse drug events and drug-drug interactions
with medical and consumer cannabidiol (CBD) use. Journal of Clinical Medicine, 8(7), 989. https://doi.
org/10.3390/jcm8070989
28
Woodcock, J. (2023). FDA concludes that existing regulatory frameworks for foods and supplements
are not appropriate for cannabidiol, will work with Congress on a new way forward. Food and Drug
Administration (FDA). https://www.fda.gov/news-events/press-announcements/fda-concludes-existing-
regulatory-frameworks-foods-and-supplements-are-not-appropriate-cannabidiol
29
Food and Drug Administration (FDA). (2021). FDA regulation of cannabis and cannabis-derived
products, including cannabidiol (CBD). https://www.fda.gov/news-events/public-health-focus/fda-
regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd
30
Sholler, D. J., Schoene, L., & Spindle, T. R. (2020). Therapeutic ecacy of cannabidiol (CBD): A review
of the evidence from clinical trials and human laboratory studies. Current Addiction Report, 7(3), 405-
412. https://doi.org/10.1007/s40429-020-00326-8
31
Cash, M. C., Cunnane, K., Fan, C., & Romero-Sandoval, E. A. (2020). Mapping cannabis potency
in medical and recreational programs in the United States. PLoS One, 15(3), e0230167. https://doi.
org/10.1371/journal.pone.0230167
32
Gurley, B. J., Murphy, T. P., Gul, W., Walker, L. A., & ElSohly, M. (2020). Content versus label claims
in cannabidiol (CBD)-containing products obtained from commercial outlets in the state of Mississippi.
Journal of Dietary Supplements, 17(5), 599-607. https://doi.org/10.1080/19390211.2020.1766634
33
Bonn-Miller, M. O., Loin, M. J. E., Thomas, B. F., Marcu, J. P., Hyke, T., & Vandrey, R. (2017). Labeling
accuracy of cannabidiol extracts sold online. JAMA, 318(17), 1708-1709. https://doi.org/10.1001/
jama.2017.11909
34
Liebling, J. P., Clarkson, N. J., Gibbs, B. W., Yates, A. S., & O’Sullivan, S. E. (2022). An analysis of
over-the-counter cannabidiol products in the United Kingdom. Cannabis and Cannabinoid Research
Journal, 7(2), 207-213. https://doi.org/10.1089/can.2019.0078
35
Miller, K. K., & Klein, J. D. (2020). Medical cannabinoid products in children and adolescents. Pediatrics
in Review, 41(5), 262-264. https://doi.org/10.1542/pir.2019-0083